S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
pixel
pixel
Log in
NASDAQ:STIM

Neuronetics Competitors

$15.39
+0.36 (+2.40 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.52
Now: $15.39
$15.70
50-Day Range
$11.67
MA: $17.16
$21.27
52-Week Range
$1.25
Now: $15.39
$22.43
Volume632,524 shs
Average Volume590,801 shs
Market Capitalization$292.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.05

Competitors

Neuronetics (NASDAQ:STIM) Vs. CERS, LMAT, KIDS, CRY, SIBN, and TCMD

Should you be buying STIM stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Neuronetics, including Cerus (CERS), LeMaitre Vascular (LMAT), OrthoPediatrics (KIDS), CryoLife (CRY), SI-BONE (SIBN), and Tactile Systems Technology (TCMD).

Cerus (NASDAQ:CERS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cerus and Neuronetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerus00303.00
Neuronetics00503.00

Cerus presently has a consensus price target of $7.8333, indicating a potential upside of 24.73%. Neuronetics has a consensus price target of $19.25, indicating a potential upside of 25.08%. Given Neuronetics' higher possible upside, analysts plainly believe Neuronetics is more favorable than Cerus.

Profitability

This table compares Cerus and Neuronetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerus-73.72%-63.47%-30.82%
Neuronetics-61.44%-88.76%-36.14%

Volatility & Risk

Cerus has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500.

Insider and Institutional Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 63.8% of Neuronetics shares are owned by institutional investors. 6.5% of Cerus shares are owned by company insiders. Comparatively, 6.0% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cerus and Neuronetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerus$74.65 million14.15$-71,240,000.00($0.51)-12.31
Neuronetics$62.66 million4.66$-29,040,000.00($1.58)-9.74

Neuronetics has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Summary

Cerus beats Neuronetics on 7 of the 13 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and LeMaitre Vascular, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neuronetics00503.00
LeMaitre Vascular04302.43

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. LeMaitre Vascular has a consensus target price of $36.1667, indicating a potential downside of 28.78%. Given Neuronetics' stronger consensus rating and higher possible upside, research analysts clearly believe Neuronetics is more favorable than LeMaitre Vascular.

Profitability

This table compares Neuronetics and LeMaitre Vascular's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neuronetics-61.44%-88.76%-36.14%
LeMaitre Vascular15.41%12.32%8.45%

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and LeMaitre Vascular's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuronetics$62.66 million4.66$-29,040,000.00($1.58)-9.74
LeMaitre Vascular$117.23 million8.81$17.93 million$0.8857.70

LeMaitre Vascular has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats Neuronetics on 10 of the 14 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and OrthoPediatrics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neuronetics00503.00
OrthoPediatrics00403.00

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. OrthoPediatrics has a consensus target price of $54.25, indicating a potential upside of 6.21%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than OrthoPediatrics.

Profitability

This table compares Neuronetics and OrthoPediatrics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neuronetics-61.44%-88.76%-36.14%
OrthoPediatrics-34.26%-11.57%-8.79%

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 71.7% of OrthoPediatrics shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 33.6% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and OrthoPediatrics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuronetics$62.66 million4.66$-29,040,000.00($1.58)-9.74
OrthoPediatrics$72.55 million13.77$-13,730,000.00($0.87)-58.71

OrthoPediatrics has higher revenue and earnings than Neuronetics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Summary

OrthoPediatrics beats Neuronetics on 9 of the 13 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and CryoLife (NYSE:CRY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and CryoLife, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neuronetics00503.00
CryoLife00303.00

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. CryoLife has a consensus target price of $28.3333, indicating a potential upside of 11.46%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than CryoLife.

Profitability

This table compares Neuronetics and CryoLife's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neuronetics-61.44%-88.76%-36.14%
CryoLife-5.45%1.86%0.82%

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 80.9% of CryoLife shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 4.7% of CryoLife shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and CryoLife's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuronetics$62.66 million4.66$-29,040,000.00($1.58)-9.74
CryoLife$276.22 million3.59$1.72 million$0.3182.00

CryoLife has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Summary

CryoLife beats Neuronetics on 7 of the 13 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and SI-BONE, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neuronetics00503.00
SI-BONE00503.00

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. SI-BONE has a consensus target price of $30.60, indicating a potential upside of 0.69%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than SI-BONE.

Profitability

This table compares Neuronetics and SI-BONE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neuronetics-61.44%-88.76%-36.14%
SI-BONE-61.67%-45.03%-29.29%

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. Comparatively, 65.3% of SI-BONE shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 15.5% of SI-BONE shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neuronetics and SI-BONE's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuronetics$62.66 million4.66$-29,040,000.00($1.58)-9.74
SI-BONE$67.30 million14.61$-38,400,000.00($1.55)-19.61

Neuronetics has higher earnings, but lower revenue than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Summary

SI-BONE beats Neuronetics on 7 of the 12 factors compared between the two stocks.

Neuronetics (NASDAQ:STIM) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Neuronetics and Tactile Systems Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neuronetics-61.44%-88.76%-36.14%
Tactile Systems Technology-4.57%1.37%0.99%

Analyst Ratings

This is a summary of recent ratings and target prices for Neuronetics and Tactile Systems Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neuronetics00503.00
Tactile Systems Technology01302.75

Neuronetics currently has a consensus target price of $19.25, indicating a potential upside of 25.08%. Tactile Systems Technology has a consensus target price of $61.75, indicating a potential upside of 26.87%. Given Tactile Systems Technology's higher possible upside, analysts clearly believe Tactile Systems Technology is more favorable than Neuronetics.

Valuation & Earnings

This table compares Neuronetics and Tactile Systems Technology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuronetics$62.66 million4.66$-29,040,000.00($1.58)-9.74
Tactile Systems Technology$189.49 million5.01$10.97 million$0.5686.91

Tactile Systems Technology has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Neuronetics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of Neuronetics shares are held by institutional investors. 6.0% of Neuronetics shares are held by company insiders. Comparatively, 5.3% of Tactile Systems Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Tactile Systems Technology beats Neuronetics on 8 of the 14 factors compared between the two stocks.


Neuronetics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cerus logo
CERS
Cerus
1.5$6.28+2.9%$1.06 billion$74.65 million-16.10Earnings Announcement
Unusual Options Activity
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$50.78+1.2%$1.03 billion$117.23 million54.60Earnings Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$51.08+0.6%$998.87 million$72.55 million-35.47Insider Selling
Decrease in Short Interest
News Coverage
CryoLife logo
CRY
CryoLife
1.8$25.42+1.1%$990.29 million$276.22 million-66.89
SI-BONE logo
SIBN
SI-BONE
1.2$30.39+2.1%$983.45 million$67.30 million-18.99Upcoming Earnings
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.6$48.67+2.6%$949.45 million$189.49 million-108.15
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$46.19+1.0%$893.04 million$459.95 million38.49Earnings Announcement
Analyst Upgrade
Analyst Revision
AngioDynamics logo
ANGO
AngioDynamics
1.4$21.55+2.2%$818.12 million$264.16 million-4.82
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$11.13+0.4%$798.39 million$154.60 million-48.39Earnings Announcement
Analyst Report
Intersect ENT logo
XENT
Intersect ENT
1.2$23.70+1.3%$775.44 million$109.14 million-12.41Upcoming Earnings
Surmodics logo
SRDX
Surmodics
1.5$54.18+1.3%$745.30 million$94.86 million677.25
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.27+4.9%$711.69 million$123.86 million71.18Earnings Announcement
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$27.77+5.8%$703.75 millionN/A-12.23
Vapotherm logo
VAPO
Vapotherm
1.5$23.44+6.8%$604.92 million$48.10 million-11.16Analyst Revision
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$38.70+1.3%$550.12 million$114.51 million-82.34
Acutus Medical logo
AFIB
Acutus Medical
1.5$19.39+8.1%$539.93 million$2.84 million0.00News Coverage
AVITA Medical logo
RCEL
AVITA Medical
1.4$23.43+2.0%$506.77 million$14.26 million-11.32Analyst Report
Gap Down
SeaSpine logo
SPNE
SeaSpine
1.3$18.17+4.6%$502.09 million$159.08 million-10.88Earnings Announcement
Analyst Report
Analyst Revision
Accuray logo
ARAY
Accuray
2.3$5.31+5.6%$493.29 million$382.93 million37.93
iCAD logo
ICAD
iCAD
1.3$20.39+7.8%$468.83 million$31.34 million-21.46Analyst Report
High Trading Volume
Analyst Revision
Gap Down
Profound Medical logo
PROF
Profound Medical
1.4$21.77+3.3%$441.02 million$4.17 million-18.61Earnings Announcement
Analyst Upgrade
Analyst Revision
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.2$22.46+5.6%$437.18 million$11.22 million-51.05Decrease in Short Interest
Co-Diagnostics logo
CODX
Co-Diagnostics
1.7$14.31+2.9%$404.53 million$220,000.0017.67Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.4$52.94+0.4%$396.79 million$198.38 million26.47
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.00+5.0%$388.58 million$24.95 million-27.27Upcoming Earnings
Apyx Medical logo
APYX
Apyx Medical
1.0$10.88+4.7%$372.91 million$28.15 million-23.15
Utah Medical Products logo
UTMD
Utah Medical Products
1.0$87.20+0.9%$317.41 million$46.90 million27.51
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$2.03+9.4%$300.35 million$8.34 million-2.94
PAVmed logo
PAVM
PAVmed
1.2$4.15+4.8%$298.40 millionN/A-5.46Unusual Options Activity
IRadimed logo
IRMD
IRadimed
1.7$23.38+1.6%$286.87 million$38.52 million73.06Decrease in Short Interest
Soliton logo
SOLY
Soliton
1.2$13.19+2.7%$279.50 millionN/A-17.59
TELA
TELA Bio
2.1$16.69+4.4%$240.87 million$15.45 million-5.74
Titan Medical logo
TMDI
Titan Medical
0.7$1.99+7.0%$214.26 millionN/A199.00Increase in Short Interest
News Coverage
Gap Down
DarioHealth logo
DRIO
DarioHealth
0.9$25.50+8.6%$206.91 million$7.56 million-3.19Upcoming Earnings
High Trading Volume
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$15.19+1.1%$196.36 millionN/A0.00Upcoming Earnings
PolyPid logo
PYPD
PolyPid
1.4$11.21+4.9%$191.09 millionN/A0.00Decrease in Short Interest
NMRD
Nemaura Medical
0.2$7.77+2.3%$178.17 millionN/A-38.85Increase in Short Interest
Repro Med Systems logo
KRMD
Repro Med Systems
2.2$3.76+0.5%$165.23 million$23.16 million-376.00Upcoming Earnings
Increase in Short Interest
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.5$6.08+3.8%$157.98 million$50.71 million-4.90Analyst Downgrade
Unusual Options Activity
Gap Up
Avinger logo
AVGR
Avinger
1.3$1.63+4.9%$138.42 million$9.13 million-1.24Upcoming Earnings
Venus Concept logo
VERO
Venus Concept
1.9$2.47+8.1%$132.27 million$110.41 million-0.74Increase in Short Interest
Liquidia logo
LQDA
Liquidia
1.5$2.82+3.5%$122.21 million$8.07 million-1.32Upcoming Earnings
Beyond Air logo
XAIR
Beyond Air
1.7$5.89+1.0%$120.67 million$1.39 million-3.75
Brainsway logo
BWAY
Brainsway
1.3$8.85+1.1%$98.46 million$23.10 million-27.66Decrease in Short Interest
LNSR
LENSAR
1.7$8.81+0.5%$93.73 millionN/A0.00Upcoming Earnings
Analyst Report
PDEX
Pro-Dex
0.9$24.26+6.2%$93.67 million$34.83 million26.97Gap Up
Nephros logo
NEPH
Nephros
2.0$8.37+1.1%$82.53 million$10.33 million-18.19Earnings Announcement
Increase in Short Interest
Gap Up
Delcath Systems logo
DCTH
Delcath Systems
1.4$19.50+1.1%$80.28 million$1.58 million-0.02
Sensus Healthcare logo
SRTS
Sensus Healthcare
1.1$4.21+17.1%$69.47 million$27.26 million-10.02Earnings Announcement
Analyst Report
STRATA Skin Sciences logo
SSKN
STRATA Skin Sciences
1.5$1.73+13.3%$58.42 million$31.59 million-12.36Gap Up
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.